CLEC12a-binding polypeptides and uses thereof

Abstract

To provide CLEC12a-binding polypeptides and methods of using CLEC12a-binding polypeptides to treat, for example, leukemia.SOLUTION: There are provided herein, VHH-containing polypeptides that bind CLEC12a, and uses of the VHH-containing polypeptides.SELECTED DRAWING: None

Description

[Technical Field]

[0001] [CROSS-REFERENCE TO RELATED APPLICATIONS] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 843,411, filed May 4, 2019, and U.S. Provisional Application No. 62 / 844,426, filed May 7, 2019, each of which is incorporated herein by reference in its entirety for all purposes.

[0002] The present invention relates to CLEC12a-binding polypeptides and methods of using CLEC12a-binding polypeptides to modulate the biological activity of CLEC12a, including, but not limited to, methods of treating cancer. [Background technology]

[0003] CLEC12a, also known as CLL-1, CLL1, DCAL-2, MICL, CD371, or C-type lectin domain family 12 member A, is a member of the C-type lectin / C-type lectin-like domain (CTL / CTLD) superfamily and regulates myeloid cell activation. CLEC12a is also a marker for blasts and leukemia stem cells in patients with acute myeloid leukemia (AML). Furthermore, CLEC12a has been used to detect minimal residual disease in patients after treatment for AML. Therefore, more potent treatments for CLEC12a-expressing cancers are therapeutically needed. Summary of the Invention [Problem to be solved by the invention]

[0004] Provided herein are CLEC12a-binding polypeptides and methods of using the CLEC12a-binding polypeptides to treat, for example, leukemia. In some embodiments, the CLEC12a-binding polypeptide comprises at least one VHH domain. Some embodiments are described below. [Means for solving the problem]

[0005] Embodiment 1. A polypeptide comprising at least one VHH domain that binds to CLEC12a, wherein the CDR1 comprises the amino acid sequence of SEQ ID NO:47, SEQ ID NO:32, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:41, or SEQ ID NO:44; CDR2 comprises the amino acid sequence of SEQ ID NO:48, SEQ ID NO:33, SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, or SEQ ID NO:45; and CDR3 comprises the amino acid sequence of SEQ ID NO:49, SEQ ID NO:34, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:43, or SEQ ID NO:46. Embodiment 2. The polypeptide of embodiment 1, wherein at least one VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 47 or SEQ ID NO: 23, a CDR2 comprising the amino acid sequence of SEQ ID NO: 48 or SEQ ID NO: 24, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49 or SEQ ID NO: 25. Embodiment 3. A polypeptide of embodiment 1 or embodiment 2, wherein at least one VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 32 or SEQ ID NO: 3, a CDR2 comprising the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO: 4, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 5. Embodiment 4. At least one VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:35, a CDR2 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:36, and a CDR3 comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:37. Any one of the polypeptides 1 to 3. Embodiment 5. A polypeptide of any one of embodiments 1 to 4, wherein at least one VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 38, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 39, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 40. Embodiment 6. A polypeptide of any one of embodiments 1 to 5, wherein at least one VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 41, a CDR2 comprising the amino acid sequence of SEQ ID NO: 16 or SEQ ID NO: 42, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 43. Embodiment 7. The polypeptide of any one of embodiments 1 to 6, wherein at least one VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 44, a CDR2 comprising the amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 45, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 46. Embodiment 8. A polypeptide of any one of embodiments 1 to 7, wherein at least one VHH domain comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34; SEQ ID NO:47, SEQ ID NO:48, and SEQ ID NO:49; SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5; SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13; SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17; SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21; SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25; SEQ ID NO:35, SEQ ID NO:36, and SEQ ID NO:37; SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40; SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43; SEQ ID NO:44, SEQ ID NO:45, and SEQ ID NO:46, respectively. Embodiment 9. The polypeptide of any one of embodiments 1 to 8, wherein at least one VHH domain is humanized. Embodiment 10. The polypeptide of any one of embodiments 1 to 9, wherein at least one VHH domain comprises an amino acid sequence that is at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of SEQ ID NO:26, SEQ ID NO:94, SEQ ID NO:31, SEQ ID NO:99, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, or SEQ ID NO:98. Embodiment 11. The polypeptide of any one of embodiments 1 to 9, wherein at least one VHH domain comprises the amino acid sequence of SEQ ID NO:26, SEQ ID NO:94, SEQ ID NO:31, SEQ ID NO:99, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, or SEQ ID NO:98. Embodiment 12. The polypeptide of any one of embodiments 1 to 8, wherein at least one VHH domain comprises an amino acid sequence that is at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, or SEQ ID NO:93. Embodiment 13. The polypeptide of any one of embodiments 1 to 8, wherein at least one VHH domain comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, or SEQ ID NO:93. Embodiment 14. The polypeptide of any one of embodiments 1 to 13, comprising two VHH domains. Embodiment 15. The polypeptide of any one of embodiments 1 to 13, comprising three VHH domains. Embodiment 16. The polypeptide of any one of embodiments 1 to 15, wherein the polypeptide comprises at least one binding domain that binds to an antigen other than CLEC12a. Embodiment 17. The polypeptide binds to CD3, T cell receptor (TCR) alpha, TCR beta, CD28, CD16, CD32A, CD64, CD89, NKp46, or NKG2D. 17. The polypeptide of embodiment 16, comprising at least one binding domain binding to Embodiment 18 The polypeptide of embodiment 14 or 15, wherein each VHH domain binds to CLEC12a. Embodiment 19. The polypeptide of embodiment 18, wherein each VHH domain comprises the same CDR1, CDR2, and CDR3 amino acid sequences. Embodiment 20. The polypeptide of embodiment 18, wherein each VHH domain comprises the same VHH sequence. Embodiment 21. The polypeptide of any one of embodiments 1 to 13, comprising one VHH domain. Embodiment 22. The polypeptide of any one of embodiments 1 to 21, wherein the polypeptide comprises an Fc region. Embodiment 23. The polypeptide of embodiment 22, wherein the Fc region comprises an amino acid sequence selected from SEQ ID NO: 50 to SEQ ID NO: 85. Embodiment 24 The polypeptide of embodiment 22 or embodiment 23, which forms a dimer under physiological conditions. Embodiment 25 The polypeptide of any one of embodiments 1 to 24, wherein CLEC12a is human CLEC12a. Embodiment 26 The polypeptide of embodiment 25, wherein human CLEC12a comprises the sequence of SEQ ID NO:1. Embodiment 27. An immunoconjugate comprising the polypeptide of any one of embodiments 1 to 26 and a cytotoxic agent. Embodiment 28. The immunoconjugate of embodiment 27, wherein the cytotoxic agent is selected from a calicheamicin, an auristatin, a dolastatin, a tublysin, a maytansinoid, a cryptophycin, a duocarmycin, an esperamicin, a pyrrolobenzodiazepine, and an enediyne antibiotic. Embodiment 29. A pharmaceutical composition comprising the polypeptide of any one of embodiments 1 to 26 or the immunoconjugate of embodiment 27 or embodiment 28, and a pharmaceutically acceptable carrier. Embodiment 30. An isolated nucleic acid encoding the polypeptide of any one of embodiments 1-26. Embodiment 31. A vector comprising the nucleic acid of embodiment 30. Embodiment 32. A host cell comprising the nucleic acid of embodiment 34 or the vector of embodiment 31. Embodiment 33. A host cell expressing the polypeptide of any one of embodiments 1 to 26. Embodiment 34. A method for producing a polypeptide of any one of embodiments 1 to 26, comprising incubating a host cell of embodiment 32 or embodiment 33 under conditions suitable for expression of the polypeptide. Embodiment 35 The method of embodiment 34, further comprising isolating the polypeptide. Embodiment 36. A method for treating cancer, comprising administering to a subject with cancer a pharmaceutically effective amount of a polypeptide of any one of embodiments 1 to 26, an immunoconjugate of embodiment 27 or embodiment 28, or a pharmaceutical composition of embodiment 29. Embodiment 37. The method of embodiment 36, wherein the cancer is selected from lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-dividing cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), hairy cell leukemia, and chronic myeloblastic leukemia. Embodiment 38. The method of embodiment 36 or 37, wherein the cancer is acute myeloid leukemia (AML). Embodiment 39 The method of any one of embodiments 36-38, further comprising administering an additional therapeutic agent. Embodiment 40. The method of embodiment 39, wherein the additional therapeutic agent is an anti-cancer agent. Embodiment 41. The method of embodiment 40, wherein the anti-cancer agent is selected from a chemotherapeutic agent, an anti-cancer biologic, radiation therapy, a CAR-T therapy, and an oncolytic virus. Embodiment 42 The method of any one of embodiments 36-39, wherein the cancer is a CLEC12a-expressing cancer. [Brief explanation of the drawings]

[0006] [Figure 1A-1B]

[0023] Figure 1A shows bio-layer interferometry data for polypeptides comprising a VHH domain that binds to CLEC12a. Figure 1A shows bio-layer interferometry data for hzMB11v13 compared to other CLEC12a-binding sdAbs described herein. Figure 1B shows bio-layer interferometry data for hzME06v16 compared to other CLEC12a-binding sdAbs described herein. [Figure 2A-2L] Figure 2 shows the binding of certain single domain antibodies (sdAbs) to CLEC12a expressed on HEK293 cells. "CLEC12a-HEK-293" refers to HEK293 cells transfected with a plasmid encoding CLEC12a as described in Example 2. "HEK-293" refers to untransfected HEK293 cells. Figure 2A shows the binding of MB11-IgG1 to CLEC12a. Figure 2B shows the binding of hzMB11v13-IgG1 to CLEC12a. Figure 2C shows the binding of ME06-IgG1 to CLEC12a. Figure 2D shows the binding of hzME06v16-IgG1 to CLEC12a. Figure 2E shows the binding of MC02-IgG1 to CLEC12a. Figure 2F shows the binding of hzMC02v6-IgG1 to CLEC12a. Figure 2G shows binding of MH07-IgG1 to CLEC12a. Figure 2H shows binding of hzMH07v3-IgG1 to CLEC12a. Figure 2I shows binding of MC06-IgG1 to CLEC12a. Figure 2J shows binding of hzMC06v2-IgG1 to CLEC12a. Figure 2K shows binding of ME02-IgG1 to CLEC12a. Figure 2L shows binding of hzME02v4-IgG1 to CLEC12a. DETAILED DESCRIPTION OF THE INVENTION

[0007] Embodiments presented herein relate to CLEC12a-binding polypeptides and their use in various methods of treating cancer.

[0008] Definitions and Various Embodiments The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0009] All references cited herein, including patent applications, patent publications, and Genbank accession numbers, are incorporated herein by reference to the same extent as if each individual reference was specifically and individually indicated to be incorporated herein by reference in its entirety.

[0010] The techniques and procedures described or referenced herein are generally well understood and generally described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F.M. Ausubel, et al. eds., (2003)), the series METHODS DS IN ENZYMOLOGY (Academic Press, Inc.), PCR 2: A PRACTICAL APPROACH (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R. I. Freshney, ed. (1987)), Oligonucleotide Synthesis (M. J. Gait, ed., 1984), Methods in Molecular Biology, Humana Press, Cell Biology: A Laboratory Notebook (J. E. Cellis, ed., 1998) Academic Press, Animal Cell Culture (R. I. Freshney, ed., 1987), Introduction to Cell and Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press, Cell and Tissue Culture Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell eds., 1993 - 8) J. Wiley and Sons, Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, eds.), Gene Transfer Vectors for Mammalian Cells (J. M. Miller and M. P. Calos, eds., 1987), PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994), Current Protocols in Immunology (J. E. Coligan et al., eds., 1991), Short Protocols in Molecular Biology (Wiley and Sons, 1999), Immunobiology (CA Janeway and P. Travers, 1997), Antibodies (P. Finch, 1997), Antibodies: A Practical Approach (D. Catty., ed., IRL Press, 1988-1989), Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford. University Press, 2000), Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999), The Antibodies (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1995), and Cancer: Principles. and Practice of Oncology (VT DeVita et al., eds., JB Lippincott Company, 1993), and the latest editions thereof.

[0011] Unless otherwise specified, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by one of ordinary skill in the art. Further, unless otherwise required by context or expressly indicated otherwise, singular terms shall include the plural and plural terms shall include the singular. In the event of conflicts in definitions among various sources or references, the definitions set forth herein shall control.

[0012] Generally, the numbering of residues in immunoglobulin heavy chains is based on Kabat et al., Sequences of The EU index numbering is as in Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). The "Kabat-like EU index" is the residue numbering for human IgG1 EU antibodies. Refers to...

[0013] Embodiments of the invention described herein are understood to include embodiments "consisting of" and / or "consisting essentially of." As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. The use of the term "or" herein is not to be construed as meaning that alternatives are mutually exclusive.

[0014] In this application, the use of "or" means "and / or" unless expressly stated otherwise or understood by a person skilled in the art. In the context of a multiple dependent claim, the use of "or" refers to more than one preceding independent or dependent claim.

[0015] The phrases "reference sample," "reference cell," or "reference tissue" refer to a sample with at least one known characteristic that can be used as a comparison to a sample with at least one unknown characteristic. In some embodiments, a reference sample can be used as a positive or negative indicator. A reference sample can be used to compare the levels of proteins and / or mRNA present in, for example, healthy tissue with those present in a sample with an unknown characteristic. can establish the level of mRNA. In some embodiments, the reference sample is a sample from the same subject, but from a different part of the subject than the part being tested. In some embodiments, the reference sample is a sample from a tissue region surrounding or adjacent to the cancer. In some embodiments, the reference sample is not from the subject being tested, but from a subject known to have or not have the disorder of interest (e.g., a particular cancer or CLEC12a-associated disorder). In some embodiments, the reference sample is from the same subject, but from a time point before the subject developed cancer. In some embodiments, the reference sample is a sample from a benign cancer sample from the same or a different subject. When a negative reference sample is used for comparison, the expression level or amount of the molecule of interest in the negative reference sample indicates a level at which one skilled in the art would recognize the absence and / or presence of a low level of the molecule, given the present disclosure. When a positive reference sample is used for comparison, the expression level or amount of the molecule of interest in the positive reference sample indicates a level at which one skilled in the art would recognize the presence of a certain level of the molecule, given the present disclosure.

[0016] The terms "benefit," "clinical benefit," "responsiveness," and "therapeutic response," as used herein in the context of benefiting from or responding to the administration of a therapeutic agent, can be measured by assessing various endpoints, such as some degree of inhibition of disease progression, including slowing and complete halting; a reduction in the number of disease episodes and / or symptoms; a reduction in lesion size; inhibition (i.e., reduction, slowing, or complete halt) of disease cell infiltration into adjacent peripheral organs and / or tissues; inhibition (i.e., reduction, slowing, or complete halt) of disease spread; some degree of alleviation of one or more symptoms associated with the disorder; disease-free presentation after treatment, e.g., increased length of progression-free survival; increased overall survival; a higher response rate; and / or reduced mortality at a given time point after treatment. A "non-responsive" or "unresponsive" subject or cancer is one that does not meet the above criteria for "responding."

[0017] The terms "nucleic acid molecule," "nucleic acid," and "polynucleotide" are used interchangeably and may refer to a polymer of nucleotides. Such polymers of nucleotides may contain natural and / or non-natural nucleotides, including, but not limited to, DNA, RNA, and PNA. A "nucleic acid sequence" refers to the linear sequence of nucleotides contained in a nucleic acid molecule or polynucleotide.

[0018] The terms "polypeptide" and "protein" are used interchangeably to refer to polymers of amino acid residues and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or unnatural amino acid residues and may include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. This definition includes both full-length proteins and fragments thereof. These terms also include post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for purposes of this disclosure, "polypeptide" refers to proteins containing modifications (generally conservative in nature), such as deletions, additions, and substitutions to the native sequence, so long as the protein maintains a desired activity. These modifications may be deliberate, such as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts producing the protein or errors during PCR amplification.

[0019] As used herein, "CLEC12a" refers to any naturally occurring mature CLEC12a resulting from processing of a CLEC12a precursor in a cell. The term includes CLEC12a from any vertebrate origin, including mammals such as primates (e.g., humans and cynomolgus or rhesus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally occurring variants of CLEC12a, such as splice variants or allelic variants. A non-limiting exemplary human CLEC12a amino acid sequence is, for example, For example, see UniProt accession number Q5QGZ9.3. See SEQ ID NO: 1.

[0020] The term "specifically binds" to an antigen or epitope is a term well understood in the art, and methods for determining such specific binding are well known in the art. A molecule is said to exhibit "specific binding" or "preferential binding" if it reacts or associates with a particular cell or substance more frequently, more rapidly, for a longer duration, and / or with greater affinity than it reacts or associates with another cell or substance. A single domain antibody (sdAb) or VHH-containing polypeptide "specifically binds" or "preferentially binds" a target if it binds with higher affinity, avidity, more readily, and / or with a longer duration than it binds to other substances. For example, an sdAb or VHH-containing polypeptide that specifically or preferentially binds to a CLEC12a epitope is an sdAb or VHH-containing polypeptide that binds this epitope with higher affinity, avidity, more readily, and / or with a longer duration than it binds to other CLEC12a epitopes or non-CLEC12a epitopes. It is also understood by interpreting this definition that, for example, an sdAb or VHH-containing polypeptide that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. Thus, "specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding. Generally, although not necessarily, reference to binding means preferential binding. "Specificity" refers to the ability of a binding protein to selectively bind to an antigen.

[0021] The term "abrogate" or "abrogate" refers to a decrease or cessation of any phenotypic characteristic, or a decrease or cessation of the incidence, degree, or likelihood of that characteristic. "Reducing" or "abrogate" refers to a decrease, reduction, or cessation of an activity, function, and / or amount compared to a reference. In some embodiments, "reducing" or "abrogate" refers to the ability to cause an overall decrease of 10% or more. In some embodiments, "reducing" or "abrogate" refers to the ability to cause an overall decrease of 50% or more. In some embodiments, "reducing" or "abrogate" refers to the ability to cause an overall decrease of 75%, 85%, 90%, 95%, or more. In some embodiments, the amount is abrogated or reduced over a period of time relative to a control over the same period of time. As used herein, the term "inhibiting" with respect to the activity of CLEC12a refers to a decrease in CLEC12a activity, such as binding to sodium urate. In some embodiments, "inhibiting" refers to a decrease in CLEC12a activity compared to CLEC12a activity in the absence of a modulator. In some embodiments, the CLEC12a binding polypeptide inhibits binding of CLEC12a to sodium urate.

[0022] As used herein, the term "epitope" refers to a site on a target molecule (e.g., an antigen, such as a protein, nucleic acid, carbohydrate, or lipid) to which an antigen-binding molecule (e.g., an sdAb or VHH-containing polypeptide) binds. Epitopes often comprise chemically active surface arrangements of molecules, such as amino acids, polypeptides, or sugar side chains, and have specific three-dimensional structural and charge characteristics. Epitopes can be formed from both contiguous and / or juxtaposed noncontiguous residues (e.g., amino acids, nucleotides, sugars, lipid moieties) of a target molecule. Epitopes formed from contiguous residues (e.g., amino acids, nucleotides, sugars, lipid moieties) are typically retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents. Epitopes can include, but are not limited to, at least 3, at least 5, or 8-10 residues (e.g., amino acids or nucleotides). In some embodiments, an epitope is less than 20 residues (e.g., amino acids or nucleotides), less than 15 residues, or less than 12 residues in length. Two antibodies may bind to the same epitope within an antigen if they exhibit competitive binding to the antigen. In some embodiments, an epitope is a region of interest within an antigen-binding molecule. An epitope may be identified by a certain minimum distance between the CDR residues on the antigen-binding molecule and the antigen residues. In some embodiments, an epitope may be identified by the above distance and further limited to those residues involved in binding (e.g., hydrogen bonding) between the antigen-binding molecule residues and the antigen residues. An epitope may also be identified by various scans. For example, an alanine scan or an arginine scan can reveal one or more residues with which an antigen-binding molecule may interact. Unless explicitly indicated, a set of residues as an epitope does not exclude other residues from being part of the epitope for a particular antigen-binding molecule. Rather, the existence of such a set indicates a sequence (or set of types) of minimal epitopes. Thus, in some embodiments, a set of residues identified as an epitope is not an exclusive list of residues for epitopes on an antigen, but rather indicates a minimal epitope associated with the antigen.

[0023] A "non-linear epitope" or "conformational epitope" comprises discontinuous polypeptides, amino acids, and / or sugars within an antigenic protein to which an epitope-specific antigen-binding molecule binds. In some embodiments, at least one residue is discontinuous with other indicated residues of the epitope, while one or more residues may be contiguous with other residues.

[0024] A "linear epitope" comprises a contiguous polypeptide, amino acid, and / or sugar sequence within an antigenic protein to which an epitope-specific antigen-binding molecule binds. Note that in some embodiments, not all of the residues within a linear epitope need be directly bound (or involved in binding) by an antigen-binding molecule. In some embodiments, a linear epitope may be derived from immunization with a peptide that essentially consists of the sequence of the linear epitope, or may be derived from a structural section of the protein that is relatively isolated from the rest of the protein (thus, the antigen-binding molecule may interact, at least primarily, with that sequence section).

[0025] The term "antibody" is used in the broadest sense and encompasses, but is not limited to, conventional antibodies (typically comprising at least one heavy chain and at least one light chain), single-domain antibodies (sdAbs comprising at least one VHH domain and an Fc region), VHH-containing polypeptides (polypeptides comprising at least one VHH domain), and various polypeptides comprising antibody-like antigen-binding domains, including fragments of any of the above, so long as they exhibit the desired antigen-binding activity. In some embodiments, antibodies comprise a dimerization domain. Such dimerization domains include, but are not limited to, a heavy chain constant domain (comprising a CH1, hinge, CH2, and CH3; CH1 is typically paired with a light chain constant domain CL, while the hinge mediates dimerization) and an Fc region (comprising a hinge, CH2, and CH3; the hinge mediates dimerization).

[0026] The term antibody also includes, but is not limited to, chimeric antibodies, humanized antibodies, and antibodies of various species such as camel (including llama), shark, mouse, human, cynomolgus monkey, etc.

[0027] As used herein, the term "antigen-binding domain" refers to a portion of an antibody sufficient to bind to an antigen. In some embodiments, the antigen-binding domain of a conventional antibody comprises three heavy chain CDRs and three light chain CDRs. Thus, in some embodiments, the antigen-binding domain comprises a heavy chain variable region comprising CDR1-FR2-CDR2-FR3-CDR3 and any portion of FR1 and / or FR4 required to maintain antigen binding, and a light chain variable region comprising CDR1-FR2-CDR2-FR3-CDR3 and any portion of FR1 and / or FR4 required to maintain antigen binding. In some embodiments, the antigen-binding domain of an sdAb or VHH-containing polypeptide comprises the three CDRs of a VHH domain. Thus, in some embodiments, the antigen-binding domain of an sdAb or VHH-containing polypeptide comprises the three CDRs of a VHH domain. 3—A VHH domain comprising a CDR3 and any portion of FR1 and / or FR4 required to maintain binding to the antigen.

[0028] As used herein, the term "VHH" or "VHH domain" or "VHH antigen-binding domain" refers to the antigen-binding portion of a single-domain antibody, such as a camelid antibody or a shark antibody. In some embodiments, a VHH comprises three CDRs and four framework regions, designated FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In some embodiments, a VHH may be truncated at the N- or C-terminus to comprise only a partial FR1 and / or FR4, or to lack one or both of these framework regions, so long as the VHH substantially maintains antigen binding and specificity.

[0029] The terms "single domain antibody" and "sdAb" are used interchangeably herein to refer to an antibody comprising at least one monomer domain, such as a VHH domain, without a light chain, and an Fc region. In some embodiments, an sdAb is a dimer of two polypeptides, each comprising at least one VHH domain and an Fc region. As used herein, the terms "single domain antibody" and "sdAb" encompass polypeptides comprising multiple VHH domains, for example, polypeptides having the structure VHH1-VHH2-Fc or VHH1-VHH2-VHH3-Fc, where VHH1, VHH2, and VHH3 can be the same or different.

[0030] The term "VHH-containing polypeptide" refers to a polypeptide comprising at least one VHH domain. In some embodiments, a VHH polypeptide comprises two, three, or four or more VHH domains, where each VHH domain may be the same or different. In some embodiments, a VHH-containing polypeptide comprises an Fc region. In some such embodiments, a VHH-containing polypeptide may be referred to as an sdAb. Furthermore, in some such embodiments, a VHH polypeptide may form a dimer. Non-limiting structures of a VHH-containing polypeptide, also referred to as an sdAb, include VHH1-Fc, VHH1-VHH2-Fc, and VHH1-VHH2-VHH3-Fc, where VHH1, VHH2, and VHH3 may be the same or different. In some such structures, one VHH may be linked to another VHH by a linker, or one VHH may be linked to an Fc region by a linker. In some such embodiments, the linker comprises 1 to 20 amino acids, preferably 1 to 20 amino acids composed primarily of glycine and optionally serine. In some embodiments, when a VHH-containing polypeptide comprises an Fc, it forms a dimer. Thus, the structure VHH1-VHH2-Fc is considered tetravalent when it forms a dimer (i.e., the dimer has four VHH domains). Similarly, the structure VHH1-VHH2-VHH3-Fc is considered hexavalent when it forms a dimer (i.e., the dimer has six VHH domains).

[0031] The term "monoclonal antibody" refers to an antibody (including an sdAb or VHH-containing polypeptide) from a substantially homogeneous antibody population. That is, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Thus, a sample of monoclonal antibody is capable of binding to the same epitope on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies are those first described by Kohler and Milstein, 1975, Nature 256:495. They may be produced by the hybridoma method described in U.S. Pat. No. 4,816,567. Monoclonal antibodies can also be made using the techniques described in, for example, McCafferty et al., 1990, Nature 348:552-554. They can be isolated from phage libraries prepared.

[0032] The term "CDR" refers to a complementarity determining region defined by at least one specific format to one skilled in the art. In some embodiments, CDRs may be defined according to the Chothia numbering scheme, the Kabat numbering scheme, a combination of Kabat and Chothia, the AbM definition, and / or the contact definition. A VHH comprises three CDRs designated CDR1, CDR2, and CDR3.

[0033] As used herein, the term "heavy chain constant region" refers to a region comprising at least three heavy chain constant domains: CH1, hinge, CH2, and CH3. Naturally, deletions and modifications within a domain that do not alter function are included within the scope of the term "heavy chain constant region" unless otherwise specified. Non-limiting exemplary heavy chain constant regions include gamma, delta, and alpha. Non-limiting exemplary heavy chain constant regions also include epsilon and mu. Each heavy chain constant region corresponds to an antibody isotype. For example, an antibody comprising a gamma constant region is an IgG antibody, an antibody comprising a delta constant region is an IgD antibody, and an antibody comprising an alpha constant region is an IgA antibody. Furthermore, an antibody comprising a mu constant region is an IgM antibody, and an antibody comprising an epsilon constant region is an IgE antibody. A particular isotype can be further subdivided into subclasses. For example, IgG antibodies include, but are not limited to, IgG1 (containing a γ1 constant region) antibodies, IgG2 (containing a γ2 constant region) antibodies, IgG3 (containing a γ3 constant region) antibodies, and IgG4 (containing a γ4 constant region) antibodies; IgA antibodies include, but are not limited to, IgA1 (containing an α1 constant region) antibodies and IgA2 (containing an α2 constant region) antibodies; and IgM antibodies include, but are not limited to, IgM1 and IgM2.

[0034] As used herein, "Fc region" refers to a portion of a heavy chain constant region comprising CH2 and CH3. In some embodiments, the Fc region comprises a hinge, CH2, and CH3. In various embodiments, when the Fc region comprises a hinge, the hinge mediates dimerization between two Fc-containing polypeptides. The Fc region can be of any antibody heavy chain constant region isotype discussed herein. In some embodiments, the Fc region is IgG1, IgG2, IgG3, or IgG4.

[0035] As used herein, an "acceptor human framework" refers to a heavy chain variable domain (V) derived from a human immunoglobulin framework or a human consensus framework, as discussed herein. H) framework. The acceptor human framework, derived from a human immunoglobulin framework or a human consensus framework, can comprise the same amino acid sequence or can contain amino acid sequence changes. In some embodiments, the number of amino acid changes is less than 10, or less than 9, or less than 8, or less than 7, or less than 6, or less than 5, or less than 4, or less than 3 across all human frameworks within a single antigen-binding domain, such as a VHH.

[0036] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody, e.g., an sdAb or VHH-containing polypeptide) and its binding partner (e.g., an antigen). The affinity or apparent affinity of a molecule X for its partner Y is generally determined by the dissociation constant (K d ) or K d(見かけ) Affinity can be measured by conventional methods known in the art, including those described herein (e.g., ELISA K d Such methods include, but are not limited to, BIAco, KinExA, flow cytometry, and / or surface plasmon resonance devices. re™, Octet™, or methods requiring flow cytometry.

[0037] As used herein, "K" d The term "K" refers to the equilibrium dissociation constant of an antigen-binding molecule / antigen interaction. d When the term " is used, it includes d and K. d(見かけ) Includes:

[0038] In some embodiments, the K dis measured by flow cytometry using an antigen-expressing cell line and fitting the mean fluorescence measured at each antibody concentration to a nonlinear one-site binding equation (Graphpad's Prism Software). In some such embodiments, K d is K d(見かけ) is.

[0039] The term "biological activity" refers to any one or more biological properties of a molecule, whether naturally occurring as found in vivo or provided or made possible by recombinant means.

[0040] An "agonist" or "activating" antibody is an antibody that increases and / or activates the biological activity of a target antigen. In some embodiments, an agonist antibody binds to an antigen and increases its biological activity by at least about 20%, 40%, 60%, 80%, 85% or more.

[0041] An "antagonist," "blocking," or "neutralizing" antibody is an antibody that inhibits, reduces, and / or inactivates the biological activity of a target antigen. In some embodiments, a neutralizing antibody binds to an antigen and reduces its biological activity by at least about 20%, 40%, 60%, 80%, 85%, 90%, 95%, 99%, or more.

[0042] An "affinity matured" sdAb or VHH-containing polypeptide refers to an sdAb or VHH-containing polypeptide that has one or more modifications in one or more CDRs that result in an improvement in the affinity of the sdAb or VHH-containing polypeptide for its antigen compared to a parent sdAb or VHH-containing polypeptide that does not have such modifications.

[0043] As used herein, "humanized VHH" refers to a VHH in which one or more framework regions have been substantially replaced with human framework regions. In some cases, certain framework region (FR) residues of a human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized VHH may contain residues that are not found in the original VHH or human framework sequence, but are included to further refine and optimize the performance of the sdAb or VHH-containing polypeptide. In some embodiments, a humanized sdAb or VHH-containing polypeptide comprises a human Fc region. As will be understood, a humanized sequence may be identified by its primary sequence and does not necessarily indicate the process by which the antibody was generated.

[0044] An "effector-positive Fc region" is a native-sequence Fc region. Exemplary "effector functions" include Fc receptor binding, Clq binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptors), and B cell activation. Such effector functions generally require combining the Fc region with a binding domain (e.g., an antibody variable domain) and can be assessed using a variety of assays.

[0045] A "native sequence Fc region" comprises an amino acid sequence identical to that of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc regions (non-A Fc regions). These include the Fc regions of human IgG1, IgG2, IgG3, and IgG4 (A and B allotypes), native-sequence human IgG2 Fc region, native-sequence human IgG3 Fc region, and native-sequence human IgG4 Fc region, as well as naturally occurring variants thereof.

[0046] A "variant Fc region" comprises an amino acid sequence that differs from that of a native-sequence Fc region by at least one amino acid modification. In some embodiments, a "variant Fc region" comprises an amino acid sequence that differs from that of a native-sequence Fc region by at least one amino acid modification, but that retains at least one effector function of the native-sequence Fc region. In some embodiments, a variant Fc region comprises at least one amino acid substitution, e.g., about one to about ten amino acid substitutions, preferably about one to about five amino acid substitutions, in the native-sequence Fc region or the Fc region of a parent polypeptide compared to the native-sequence Fc region or the Fc region of a parent polypeptide. In some embodiments, a variant Fc region herein has at least about 80% sequence identity, at least about 90% sequence identity, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with a native-sequence Fc region and / or the Fc region of a parent polypeptide.

[0047] "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In some embodiments, the FcγR is a native human FcR. In some embodiments, the FcR binds IgG antibodies (gamma receptors), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced ​​forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences but differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (see, e.g., Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed, for example, in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991), Capel et al., Immunomethods 4:25-34 (1994), and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those identified in the future, are encompassed by the term "FcR" herein. For example, the term "Fc receptor" or "FcR" also includes the fetal receptor FcRn, which is involved in the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) and immunoglobulin G (Ig) to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)). FcRn plays a role in regulating the homeostasis of FcRn. Methods for measuring binding to FcRn are known (see, e.g., Ghetie and Ward, Immunol. Today 18(12):592-598 (1997); Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton et al., J. Biol. Chem. 279(8):6213-6216 (2004); WO 2004 / 92219 (Hinton et al.)).

[0048] As used herein, "chimeric antigen receptor" refers to an engineered polypeptide comprising an extracellular antigen-recognition domain, a transmembrane domain, and an intracellular signaling domain. In some embodiments, the extracellular antigen-recognition domain comprises a VHH domain.

[0049] As used herein, the terms "substantially similar" or "substantially the same" refer to a sufficiently high degree of similarity between two or more numerical values ​​such that one of skill in the art would consider the difference between the two or more values ​​to have little or no biological and / or statistical significance within the context of the biological characteristic measured by the values. In some embodiments, two or more substantially similar values ​​differ by no more than any one of the following round numbers: 5%, 10%, 15%, 20%, 25%, or 50%.

[0050] A polypeptide "variant" refers to a biologically active polypeptide having at least about 80% amino acid sequence identity with a native sequence polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Such variants include, for example, polypeptides in which one or more amino acid residues are added or deleted at the N- or C-terminus of the polypeptide. In some embodiments, a variant has at least about 80% amino acid sequence identity. In some embodiments, a variant has at least about 90% amino acid sequence identity. In some embodiments, a variant has at least about 95% amino acid sequence identity with a native sequence polypeptide.

[0051] As used herein, "percent (%) amino acid sequence identity" and "homology" with respect to a peptide, polypeptide, or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a particular peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment to determine percent amino acid sequence identity can be performed by one of skill in the art using publicly available computer software, for example, BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. This can be achieved in a variety of ways that are within the skill of the art. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared.

[0052] Amino acid substitutions can include, but are not limited to, replacing one amino acid in a polypeptide with another. Exemplary substitutions are shown in Table 1. Amino acid substitutions can be introduced into an antibody of interest and the product screened for a desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.

[0053] [Table 1]

[0054] Amino acids can be grouped according to common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile, (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln, (3) Acidic: Asp, Glu, (4) Basic: His, Lys, Arg, (5) Residues that affect chain orientation: Gly, Pro, (6) Aromatic: Trp, Tyr, Phe.

[0055] Non-conservative substitutions involve exchanging a member of one of these classes for another class.

[0056] The term "vector" is used to describe a polynucleotide that can be manipulated to contain cloned polynucleotide(s) that can be propagated in a host cell. A vector can contain one or more of the following elements: an origin of replication, one or more regulatory sequences (e.g., promoters and / or enhancers) that control the expression of a polypeptide of interest, and / or one or more selectable marker genes (e.g., antibiotic resistance genes and genes that can be used in colorimetric assays, e.g., β-galactosidase, etc.). The term "expression vector" refers to a vector used to express a polypeptide of interest in a host cell.

[0057] "Host cell" refers to a cell that can be or has been the recipient of a vector or isolated polynucleotide. Host cells can be prokaryotic or eukaryotic. Exemplary eukaryotic cells include mammalian cells, such as primate or non-primate cells, fungal cells, such as yeast, plant cells, and insect cells. Non-limiting exemplary mammalian cells include, but are not limited to, NSO cells, PER.C6™ cells (Crucell), and and 293 cells and CHO cells, as well as their derivatives, such as 293-6E cells, CHO-DG44 cells, CHO-K1 cells, CHO-S cells, and CHO-DS cells. A host cell includes the progeny of a single host cell, although the progeny may not be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide(s) provided herein.

[0058] As used herein, the term "isolated" refers to a molecule that is separated from at least some of the components with which it is typically found or produced in nature. For example, a polypeptide is referred to as "isolated" when it is separated from at least some of the components of the cell that produced it. If the polypeptide is secreted by a cell after expression, physically separating the supernatant containing the polypeptide from the cell that produced it is considered to "isolate" the polypeptide. Similarly, a polynucleotide is referred to as "isolated" when it is not part of a larger polynucleotide with which it is typically found in nature (e.g., in the case of a DNA polynucleotide, genomic DNA or mitochondrial DNA, etc.) or when it is separated from at least some of the components of the cell that produced it, e.g., in the case of an RNA polynucleotide. Thus, a DNA polynucleotide contained in a vector within a host cell can be referred to as "isolated."

[0059] The terms "individual" and "subject" are used interchangeably herein to refer to animals, e.g., mammals. In some embodiments, mammals include, but are not limited to, humans, rodents, monkeys, cats, dogs, horses, cows, pigs, sheep, goats, mammalian laboratory animals, mammalian farm animals, mammalian sport animals, and mammalian pets. Methods of treating animals are provided. In some instances, "individual" or "subject" refers to an individual or subject in need of treatment for a disease or disorder. In some embodiments, the subject receiving treatment may be a patient, which means the subject has been identified as having or at sufficient risk of suffering from a disorder relevant to the treatment.

[0060] As used herein, "disease" or "disorder" refers to a condition for which treatment is necessary and / or desirable.

[0061] The terms "tumor cell," "cancer cell," "cancer," "tumor," and / or "neoplasm" are used interchangeably herein, unless otherwise specified, to refer to a cell (or cells) that exhibit uncontrolled proliferation and / or abnormally increased cell survival and / or inhibited apoptosis that interferes with the normal function of bodily organs and systems. This definition includes benign and malignant cancers, blood cancers such as leukemia, lymphoma, and multiple myeloma, polyps, hyperplasias, and occult tumors or micrometastases.

[0062] The terms "cancer" and "tumor" encompass solid tumors and hematologic / lymphatic cancers, as well as malignant tumors, premalignant tumors, and benign tumors, such as dysplasia. Exemplary cancers include, but are not limited to, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and central nervous system cancer, breast cancer, peritoneal cancer, cervical cancer, choriocarcinoma, colorectal cancer, connective tissue cancer, digestive system cancer, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer (including gastrointestinal cancer), glioblastoma, liver cancer, hepatocellular carcinoma, intraepithelial neoplasia, kidney or renal cancer, laryngeal cancer, leukemia, liver cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), melanoma, myeloma, neuroblastoma, oral cancer (lip, tongue, mouth, and pharynx), ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, respiratory system cancer, salivary gland cancer, sarcoma, skin cancer, squamous cell carcinoma, stomach cancer, cancer), testicular cancer, thyroid cancer, uterine or endometrial cancer, urinary system cancer, vulvar cancer, lymphomas including Hodgkin's lymphoma and non-Hodgkin's lymphoma, and B-cell lymphomas (including low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-dividing cell NHL, and bulky disease NHL), These include: pleuromyelitis, leukemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia, and other carcinomas and sarcomas; post-transplant lymphoproliferative disorder (PTLD); and abnormal blood vessel growth associated with phacomatosis, edema (such as that associated with brain tumors), and Meigs' syndrome.

[0063] As used herein, the term "non-tumor cells" or "non-cancer cells" refers to normal cells or tissues. Exemplary non-tumor cells include, but are not limited to, T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, macrophages, epithelial cells, fibroblasts, hepatocytes, interstitial kidney cells, fibroblast-like synoviocytes, osteoblasts, and cells located in the breast, skeletal muscle, pancreas, stomach, ovary, small intestine, placenta, uterus, testis, kidney, lung, heart, brain, liver, prostate, colon, lymphoid organs, bone, and bone-derived mesenchymal stem cells. As used herein, the term "peripherally located cells or tissues" refers to non-tumor cells that are not located near tumor cells and / or within the tumor microenvironment.

[0064] As used herein, the term "cells or tissues within the tumor microenvironment" refers to cells, molecules, extracellular matrix, and / or blood vessels that surround and / or nourish tumor cells. Exemplary cells or tissues within the tumor microenvironment include, but are not limited to, tumor vasculature, tumor-infiltrating lymphocytes, fibroblastic reticular cells, endothelial progenitor cells (EPCs), cancer-associated fibroblasts, pericytes, other stromal cells, components of the extracellular matrix (ECM), dendritic cells, antigen-presenting cells, T cells, regulatory T cells (Treg cells), macrophages, neutrophils, bone marrow-derived lymphocytes, and / or tumor-associated lymphocytes. These include tumor suppressor cells (MDSCs) and other immune cells located in the vicinity of the tumor. Methods for identifying tumor cells and / or cells / tissues located within the tumor microenvironment are well known in the art, as described herein below.

[0065] In some embodiments, "increase" or "decrease" refers to a statistically significant increase or decrease, respectively. As will be apparent to one of skill in the art, "modulation" can also include causing a change (which may be either an increase or a decrease) in the affinity, avidity, specificity, and / or selectivity of a target or antigen for one or more of its ligands, binding partners, homomultimeric or heteromultimeric forms, or substrates, compared to the same conditions except for the presence of the test agent; causing a change (which may be either an increase or a decrease) in the sensitivity of a target or antigen to one or more conditions (pH, ionic strength, presence of cofactors, etc.) in the medium or environment in which the target or antigen is present; and / or cell proliferation or cytokine production. This can be determined in any suitable manner and / or using any suitable assay known per se or described herein, depending on the target involved.

[0066] As used herein, "immune response" is intended to encompass a cellular and / or humoral immune response that is sufficient to inhibit or prevent the onset of or ameliorate the symptoms of a disease (e.g., cancer or cancer metastasis). An "immune response" can encompass aspects of both the innate and adaptive immune systems.

[0067] As used herein, "treatment" refers to an approach for obtaining beneficial or desired clinical results. As used herein, "treatment" refers to any administration or application of a therapeutic agent for a disease in a mammal, including a human. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, any one or more of the following: alleviation of one or more symptoms; reduction in the extent of the disease; prevention or delay of disease progression (e.g., metastasis, e.g., to the lungs or lymph nodes); prevention or delay of disease recurrence; delay or slowing of disease progression; amelioration of the disease state; arrest of the disease or disease progression; arrest or slowing of the disease or its progression; prevention of its development; and remission (whether partial or total). "Treatment" also includes alleviation of the pathological consequences of a proliferative disease. The methods provided herein contemplate any one or more of these aspects of treatment. In accordance with the above, the term treatment does not require 100 percent elimination of all aspects of the disorder.

[0068] "Ameliorate" means that one or more symptoms are lessened or improved compared to when the therapeutic agent is not administered. "Amelioration" also includes a shortening or reduction in the duration of the symptoms.

[0069] The term "anti-cancer agent" is used herein in its broadest sense to refer to an agent used to treat one or more cancers. Exemplary classes of such agents include, but are not limited to, chemotherapeutic agents, anti-cancer biologics (such as cytokines, receptor extracellular domain-Fc fusions, and antibodies), radiation therapy, CAR-T therapy, therapeutic oligonucleotides (such as antisense oligonucleotides and siRNA), and oncolytic viruses.

[0070] The term "biological sample" refers to a quantity of material from a living or formerly living organism, including, but not limited to, blood (e.g., whole blood), plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes, and spleen.

[0071] The term "control" or "reference" in an experimental or comparative context refers to a composition known to be free of the analyte (a "negative control") or a composition known to contain the analyte. A control or reference may refer to a composition of matter (a "positive control") that is known to lack the activity of the agent being tested, such as an antibody. A positive control may contain a known concentration of the analyte. A control or reference may also refer to a control agent that is known to lack the activity of the agent being tested, such as an antibody.

[0072] As used herein, "delaying the onset of disease" means to delay, prevent, slow, retard, stabilize, inhibit, and / or prolong the onset of a disease (such as cancer). This delay can be of varying lengths of time, depending on the history of the disease and / or the individual being treated. As will be apparent to one of skill in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, late-stage cancer, such as the development of metastases, can be delayed.

[0073] As used herein, "prevention" includes providing protection against the occurrence or recurrence of a disease in a subject who may have a predisposition to the disease, but who has not yet been diagnosed with the disease. Unless otherwise indicated, the terms "reduce," "inhibit," or "prevent" do not indicate or require complete prevention over the entire period of time, but rather prevention only over the period of time being measured.

[0074] A "therapeutically effective amount" of a substance / molecule, agonist, or antagonist can vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance / molecule, agonist, or antagonist to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the substance / molecule, agonist, or antagonist are outweighed by the therapeutically beneficial effects. A therapeutically effective amount can be delivered in one or more administrations. A therapeutically effective amount refers to an amount effective, at the necessary dosages, for the necessary periods of time, to achieve a desired therapeutic and / or prophylactic result.

[0075] The terms "pharmaceutical formulation" and "pharmaceutical composition" are used interchangeably and refer to a preparation that is in a form that allows the biological activity of the active ingredient(s) to be effective and that does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered. Such formulations may be sterile.

[0076] A "pharmaceutically acceptable carrier" refers to a non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, formulation aid, or carrier conventional in the art used with therapeutic agents that together comprise a "pharmaceutical composition" for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. A pharmaceutically acceptable carrier is appropriate for the formulation with which it is used.

[0077] Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

[0078] The term "concurrently" is used herein to refer to the administration of two or more therapeutic agents where at least a portion of the administration overlaps in time, or where the administration of one therapeutic agent is brief relative to the administration of the other, or where the therapeutic effects of both therapeutic agents overlap for at least some period of time.

[0079] The term "sequentially" is used herein to refer to the administration of two or more therapeutic agents that do not overlap in time or where the therapeutic effects of the therapeutic agents do not overlap.

[0080] As used herein, "in combination with" refers to the administration of one therapy in addition to another. Thus, "in combination with" refers to the administration of one therapy before, during, or after the administration of another therapy to an individual.

[0081] The term "package insert" is used to refer to instructions customarily included in commercial packaging of a therapeutic product, which contain information regarding directions, use, dosage, administration, concomitant therapy, contraindications and / or warnings regarding the use of such therapeutic product.

[0082] An "article of manufacture" is any product (e.g., package or container) or kit that includes at least one reagent, e.g., a pharmaceutical agent for treating a disease or disorder (e.g., cancer), or a probe that specifically detects a biomarker described herein. In some embodiments, the product or kit is advertised, delivered, or sold as a unit for performing a method described herein.

[0083] The terms "label" and "detectable label" refer to a moiety that, for example, when attached to an antibody or antigen, renders the reaction (e.g., binding) between members of a specific binding pair detectable. A labeled member of a specific binding pair is said to be "detectably labeled." Thus, the term "labeled binding protein" refers to a protein into which a label has been incorporated that provides for the identification of the binding protein. In some embodiments, the label is a detectable marker that can generate a signal that is detectable visually or by instrumental means, for example, the incorporation of a radiolabeled amino acid or the attachment of a biotinyl moiety to the polypeptide that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or an enzymatic activity that can be detected by optical or colorimetric methods). Examples of labels for polypeptides include, but are not limited to, radioisotopes or radionuclides (e.g., 3 H, 14 C. 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, or 153Sm), chromogens, fluorescent labels (e.g., FITC, rhodamine, lanthanide fluorophores), enzyme labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by secondary reporters (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), and magnetic agents such as gadolinium chelates. Representative examples of labels commonly used in immunoassays include light-emitting moieties, e.g., acridinium compounds, and fluorescent moieties, e.g., fluorescein. In this regard, the moiety itself may not be detectably labeled, but may become detectable upon reaction with yet another moiety.

[0084] Exemplary CLEC12a-Binding Polypeptides Provided herein are CLEC12a-binding polypeptides. In various embodiments, the CLEC12a-binding polypeptides comprise at least one VHH domain that binds to CLEC12a. In some embodiments, the CLEC12a is human CLEC12a. In some embodiments, the CLEC12a-binding polypeptides block the binding of CLEC12a to a ligand. In some embodiments, the CLEC12a-binding polypeptides provided herein comprise one, two, three, four, five, six, seven, or eight VHH domains that bind to CLEC12a. In some embodiments, the CLEC12a-binding polypeptides provided herein comprise one, two, three, or four VHH domains that bind to CLEC12a. The CLEC12a-binding polypeptides may comprise one or more VHH domains that bind to one or more target proteins other than CLEC12a. Such polypeptides may be referred to as "multispecific" polypeptides.

[0085] In some embodiments, a CLEC12a-binding polypeptide comprises at least one VHH domain that binds to CLEC12a and an Fc region. In some embodiments, a CLEC12a-binding polypeptide provided herein comprises one, two, three, or four VHH domains and an Fc region. In some embodiments, the Fc region mediates dimerization of CLEC12a-binding polypeptides under physiological conditions, and the formation of dimers doubles the number of CLEC12a-binding sites. For example, a CLEC12a-binding polypeptide comprising three VHH domains that bind to CLEC12a and an Fc region is trivalent as a monomer, but under physiological conditions, the Fc region can mediate dimerization, and the CLEC12a-binding polypeptide exists as a hexavalent dimer under such conditions.

[0086] In some embodiments, a CLEC12a-binding polypeptide comprises at least two VHH domains, where a first VHH domain binds to a first epitope on CLEC12a and a second VHH domain binds to a second epitope on CLEC12a. When a CLEC12a-binding polypeptide comprises a VHH domain that binds to a first epitope on CLEC12a and a VHH domain that binds to a second epitope on CLEC12a, the CLEC12a-binding polypeptide may be referred to as "dual epitopic" or "bispecific." In some embodiments, a CLEC12a-binding polypeptide comprises at least two VHH domains, where a first VHH domain binds to CLEC12a and a second VHH domain binds to an antigen other than CLEC12a. Such polypeptides may be referred to as "bispecific" or "multispecific."

[0087] Non-limiting exemplary CLEC12a-binding polypeptides are shown in Table 2. The sequences for the indicated single domain antibodies are shown in certain sequence tables herein. Polypeptide names beginning with "hz" indicate that they are humanized versions of the corresponding parent polypeptide.

[0088] [Table 2]

[0089] CLEC12a-binding polypeptide In various embodiments, the VHH domain that binds to CLEC12a comprises a CDR1 sequence selected from SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:41, SEQ ID NO:44, and SEQ ID NO:47; a CDR2 sequence selected from SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:45, and SEQ ID NO:48; and a CDR3 sequence selected from SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:25, SEQ ID NO:34, SEQ ID NO:37, SEQ ID NO:40, SEQ ID NO:43, SEQ ID NO:46, and SEQ ID NO:49. In various embodiments, the VHH domain that binds to CLEC12a comprises CDR1, CDR2, and CDR3 sequences selected from SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5; SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13; SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17; SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21; SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25; SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34; SEQ ID NO:35, SEQ ID NO:36, and SEQ ID NO:37; SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40; SEQ ID NO:41, SEQ ID NO:42, and SEQ ID NO:43; SEQ ID NO:44, SEQ ID NO:45, and SEQ ID NO:46; and SEQ ID NO:47, SEQ ID NO:48, and SEQ ID NO:49. In various embodiments, the VHH domain is humanized.

[0090] In some embodiments, the VHH domain that binds to CLEC12a comprises an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, and SEQ ID NO:99. In some embodiments, the VHH domain that binds to CLEC12a comprises an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, and SEQ ID NO:99.

[0091] In various embodiments, the CLEC12a binding polypeptide comprises one, two, three or four VHH domains that bind to CLEC12a.

[0092] In various embodiments, the CLEC12a-binding polypeptide comprises at least one VHH domain that binds to CLEC12a and at least one VHH domain that binds to a natural killer cell antigen or a T cell antigen. In some such embodiments, the CLEC12a-binding polypeptide may be referred to as a multispecific antibody.

[0093] In some embodiments, the CLEC12a-binding polypeptide comprises at least one VHH domain described herein fused to an Fc region. In some embodiments, the Fc region has a sequence selected from SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, and SEQ ID NO:85.

[0094] In some embodiments, the VHH domain that binds to CLEC12a is humanized. Humanized antibodies (such as sdAbs or VHH-containing polypeptides) are useful as therapeutic molecules because they reduce or eliminate human immune responses to non-human antibodies, which can result in an immune response against antibody therapeutics and reduce the efficacy of the therapeutic. Generally, a humanized antibody comprises one or more variable domains in which the CDRs (or portions thereof) are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. Optionally, the humanized antibody also comprises at least a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve the specificity or affinity of the antibody.

[0095] Humanized antibodies and methods for making them are reviewed, for example, in Almagro and Fransson, (2008) Front. Biosci. 13: 1619-1633, and are also described in, for example, Riechmann et al., (1988) Nature 332:323-329, Queen et al., (1989) Proc. Natl Acad. Sci. USA 86: 10029-10033, U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409, Kashmiri et al., (2005) Methods 36:25-34, Padlan, (1991) Mol. Immunol. 28:489-498 (describing "resurfacing"), Dall'Acqua et al. al., (2005) Methods 36:43-60 (describing "FR shuffling"), and Osbourn et al., (2005) Methods 36:61-68 and Klimka et al., (2000) Br. J. Cancer, 83:252-260 (describing a "guided selection" approach to FR shuffling).

[0096] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (e.g., Sims et al. (1993) J. Immunol. 151:2296), framework regions derived from consensus sequences of human antibodies of a particular subgroup of heavy chain variable regions (see, e.g., Carter et al. (1992) Proc. Natl. Acad. Sci. USA, 89:4285, and Presta et al. (1993) J. Immunol. 151:2623), human mature (somatically mutated) framework regions, or human germline Framework regions (see, e.g., Almagro and Fransson, (2008) Front. Biosci. 13:1619-1633), and framework regions obtained from screening FR libraries (see, e.g., Baca et al., (1997) J. Biol. Chem. 272: 10678-10684, and Rosok et al., (1996) J. Biol. Chem. 271:22611-22618). Typically, VHHs A humanized VHH is produced by replacing the FR region with a human FR region. In some embodiments, replacing certain FR residues of the human FR improves one or more properties of the humanized VHH. A VHH domain having such replaced residues is also referred to herein as "humanized."

[0097] In various embodiments, the Fc region comprised in the CLEC12a-binding polypeptide is or is derived from a human Fc region.

[0098] In some embodiments, the Fc region included in the CLEC12a-binding polypeptide is derived from a human Fc region and contains three amino acid deletions in the lower hinge corresponding to IgG1 E233, L234, and L235, and is referred to herein as "Fc xELL." Because Fc xELL polypeptides do not bind to FcγR, they are referred to as "effector silent" or "effector null," although in some embodiments, the xELL Fc region binds to FcRn, resulting in extended half-life and transcytosis associated with FcRn-mediated recycling.

[0099] In some embodiments, the Fc region comprised in the CLEC12a-binding polypeptide comprises , derived from the human Fc region and containing the mutations M252Y and M428V, referred to herein as "Fc-YV." In some embodiments, such mutations enhance binding to FcRn at the acidic pH of the endosome (near 6.5) while losing detectable binding at neutral pH (about 7.2), thereby enabling enhanced FcRn-mediated recycling and extended half-life.

[0100] In some embodiments, the Fc region included in the CLEC12a-binding polypeptide is derived from a human Fc region and contains mutations designed for heterodimerization, referred to herein as "knob" and "hole." In some embodiments, the "knob" Fc region contains the mutation T366W. In some embodiments, the "hole" Fc region contains the mutations T366S, L368A, and Y407V. In some embodiments, the Fc region used for heterodimerization contains an additional mutation, such as the mutation S354C on the first member of the heterodimeric Fc pair, which forms an asymmetric disulfide with the corresponding mutation Y349C on the second member of the heterodimeric Fc pair. In some embodiments, one member of the heterodimeric Fc pair contains the modification H435R or H435K to prevent Protein A binding while maintaining FcRn binding. In some embodiments, one member of the heterodimeric Fc pair comprises the modification H435R or H435K, while the second member of the heterodimeric Fc pair is not modified at H435. In various embodiments, the hole Fc region comprises the modification H435R or H435K (sometimes referred to as "hole-R" when the modification is H435R), while the knob Fc region does not. In some cases, the hole-R mutation improves purification of the heterodimer relative to a possible homodimeric hole Fc region.

[0101] Non-limiting exemplary Fc regions that can be used in CLEC12a-binding polypeptides include Fc regions comprising the amino acid sequences of SEQ ID NO:50 to SEQ ID NO:85.

[0102] Chimeric receptors and engineered cells Provided herein is a chimeric antigen receptor (CAR) having an extracellular domain comprising one or more CLEC12a-binding VHH domains provided herein. The CAR constructs provided herein comprise an extracellular domain comprising one or more CLEC12a-binding VHH domains, a transmembrane domain, and an intracellular signaling region. The one or more CLEC12a-binding VHH domains that form the antigen binding unit of the CAR bind or can bind to, i.e., target, CLEC12a binding with sufficient affinity that the CAR is therapeutically useful in targeting cells or tissues that express CLEC12a binding.

[0103] CARs are synthetic receptors that typically contain an extracellular targeting / binding moiety associated with one or more signaling domains in a single fusion molecule expressed on the surface of cells such as T cells. Thus, CARs combine antigen specificity and T cell activation properties in a single fusion molecule. First-generation CARs typically contained the cytoplasmic region of CD3ζ or the Fcl receptor γ chain as their signaling domain. First-generation CARs have been tested in phase I clinical trials in patients with ovarian cancer, renal cancer, lymphoma, and neuroblastoma, and have induced moderate responses (reviewed in Sadelain et al., Curr Opin Immunol, 21 (2): 215-223, 2009). Signaling of costimulatory molecules such as CD28 and CD3ζ is also important. Second-generation CARs, containing domains, provide dual signaling for a combination of activating and costimulatory signals. Third-generation CARs are more complex, with three or more signaling domains (reviewed in Sadelain et al., Cancer Discovery (3), 388-398, 2013 and Dotti et al., Immuno. Rev, 257 (1), 1-36, 2014).

[0104] In some embodiments, the provided CAR comprises a CLEC12a-binding VHH domain. In some embodiments, the CAR comprises at least two VHH domains that target one or more antigens. In one embodiment, the antigen-binding domain of the CAR comprises two or at least two CLEC12a-binding VHH domains, thereby providing a bivalent molecule. In one embodiment, the antigen-binding domain comprises two or at least two CLEC12a-binding VHH domains, but binds to different epitopes on CLEC12a. In such cases, the antigen-binding domain comprises a first CLEC12a-binding VHH domain that binds to a first epitope on CLEC12a and a second VHH domain that binds to a second epitope on CLEC12a. The epitopes may overlap. Thus, in some embodiments, the antigen-binding domain is biparatopic and the CAR is a biparatopic CAR. In yet another embodiment, the antigen-binding domain comprises two CLEC12a-binding VHH domains that bind to the same epitope on CLEC12a.

[0105] The transmembrane domain of the CARs provided herein is typically a domain that crosses or can cross or span the plasma membrane, and is linked directly or indirectly (e.g., via a spacer such as an immunoglobulin hinge sequence) to an endoplasmic portion comprising an extracellular antigen-binding domain and an intracellular signaling domain. In one embodiment, the transmembrane domain of the CAR is the transmembrane region of a transmembrane protein (e.g., a type I transmembrane protein), an artificial hydrophobic sequence, or a combination thereof. In one embodiment, the transmembrane domain comprises a CD3ζ domain or a CD28 transmembrane domain. Other transmembrane domains will be apparent to those skilled in the art and can be used in connection with the CAR embodiments provided herein.

[0106] The intracellular signaling region of a CAR provided herein comprises one or more intracellular signaling domains that transmit a signal to a T cell upon binding of the antigen-binding domain of the CAR, e.g., upon antigen binding. In some embodiments, the intracellular region comprises an intracellular signaling domain that is or includes an ITAM signaling domain. Exemplary intracellular signaling domains include signaling domains derived from, for example, the zeta chain of the T cell receptor complex or any of its homologs (e.g., the eta chain, the FcsRIy chain and β chain, the MB1 (Iga) chain, the B29 (Ig) chain, etc.), the human CD3 zeta chain, CD3 polypeptides (Δ, δ, and ε), syk family tyrosine kinases (e.g., Syk, ZAP70, etc.), src family tyrosine kinases (e.g., Lck, Fyn, Lyn, etc.), and other molecules involved in T cell signaling, such as CD2, CD5, OX40, and CD28. In certain embodiments, the intracellular signaling region comprises an intracellular signaling domain derived from the human CD3 zeta chain.

[0107] In some embodiments, the intracellular signaling region of the CAR can further comprise an intracellular signaling domain derived from a costimulatory molecule. In such instances, such a signaling domain can enhance CAR-T cell activity, e.g., through enhanced proliferation, survival, and / or development of memory cells, after antigen-specific binding, as compared to a CAR comprising only an ITAM-containing signaling domain, e.g., CD3ζ. In some embodiments, the costimulatory domain is a functional signaling domain obtained from a protein selected from CD28, CD137 (4-IBB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1 (CD11a / CD18), Lck, TNFR-I, TNFR-II, Fas, CD30, CD40, or a combination thereof. In certain embodiments, the costimulatory signaling domain is derived from or obtained from a human protein. In some aspects, the costimulatory signaling domain is derived from or obtained from human CD28 or human CD137 (4-IBB).

[0108] In some embodiments, the costimulatory signaling domain is derived from CD28 or 41BB. Coming.

[0109] In certain embodiments, the CAR further comprises a hinge or spacer region connecting the extracellular antigen-binding domain and the transmembrane domain. This hinge or spacer region can be used to achieve various lengths and flexibility of the resulting CAR. Examples of hinge or spacer regions that can be used include, but are not limited to, an Fc fragment of an antibody or a fragment or derivative thereof, an antibody hinge region or a fragment or derivative thereof, an antibody CH2 region, an antibody CH3 region, an artificial spacer sequence, such as a peptide sequence, or a combination thereof. Other hinge or spacer regions will be apparent to those skilled in the art and can be used. In one embodiment, the hinge is an IgG4 hinge or a CD8A hinge.

[0110] In some embodiments, the spacer and transmembrane domains are hinge and transmembrane domains derived from CD8.

[0111] Also provided herein is an isolated nucleic acid construct comprising at least one nucleic acid encoding a CAR provided herein. In some embodiments, the construct is an expression vector for expressing a CAR in cells. The expression vector can be a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 2013). For gene transfer into mammalian cells, Many viral-based systems have been developed, for example, retroviruses such as adenoviral vectors are used, and in one embodiment, lentiviral vectors are used.

[0112] In a further aspect, isolated cells or cell populations comprising one or more of the above-described nucleic acid constructs are also provided. Also provided are isolated cells or cell populations that have been genetically modified to express a CAR provided herein. Thus, provided herein are genetically engineered cells comprising, e.g., stably expressing, a CAR provided herein. In one embodiment, the cells are selected from the group consisting of T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, hematopoietic stem cells, and / or pluripotent embryonic stem cells / pluripotent induced stem cells. In some cases, the cells are T cells, such as CD4 T cells and / or CD8 T cells. In some embodiments, the cells are autologous to the subject. For example, in some embodiments, T cells can be isolated from a patient (also referred to as primary T cells) for manipulation, e.g., transfection or transduction, with a CAR nucleic acid construct.

[0113] Illustratively, primary T cells can be purified ex vivo (CD4 or CD8 cells, or both) and stimulated with TCR / CD28 agonists, such as anti-CD3 / anti-CD28 coated beads. After a two- or three-day activation process, a recombinant expression vector encoding a CAR can be stably introduced into the primary T cells through standard lentiviral or retroviral transduction protocols or plasmid electroporation strategies. Cells can be monitored for CAR expression, for example, by flow cytometry using an anti-epitope tag or an antibody that cross-reacts with the native parent molecule. CAR-expressing T cells can be enriched by sorting with an anti-epitope tag antibody, or can be enriched for high or low expression depending on the application.

[0114] CAR-engineered T cells can be assayed for appropriate function by a variety of means. In some cases, in vitro cytotoxicity, proliferation, or cytokine expression are assayed. In-situ assays (e.g., IFNγ expression) can be used to assess the functionality of engineered T cells. Exemplary standard endpoints are the percent lysis of a tumor line, the proliferation of engineered T cells, or the expression of IFNγ protein in the culture supernatant. In some cases, the ability to stimulate T cell activation upon stimulation of the CAR, for example, via an antigen, can be assessed by monitoring the expression of activation markers such as CD69, CD44, or CD62L, proliferation, and / or cytokine production.

[0115] Polypeptide Expression and Production Nucleic acid molecules are provided that comprise a polynucleotide encoding a CLEC12a-binding polypeptide. In some embodiments, the nucleic acid molecule can also encode a leader sequence that directs secretion of the CLEC12a-binding polypeptide, and the leader sequence is typically cleaved so that it is not present in the secreted polypeptide. The leader sequence can be the native heavy chain (or VHH) leader sequence, or can be another heterologous leader sequence.

[0116] The nucleic acid molecule can be constructed using recombinant DNA techniques routine in the art. In some embodiments, the nucleic acid molecule is an expression vector suitable for expression in a selected host cell.

[0117] Vectors containing nucleic acids encoding the CLEC12a-binding polypeptides described herein are provided. Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, and the like. In some embodiments, a vector optimized for expression of the polypeptide in a desired cell type, such as CHO cells or CHO-derived cells, or NSO cells, is selected. Exemplary such vectors are described, for example, in Running Deer et al., Biotechnol. Prog. 20:880-889 (2004).

[0118] In some embodiments, CLEC12a-binding polypeptides can be expressed in prokaryotic cells, such as bacterial cells, or in eukaryotic cells, such as fungal cells (such as yeast), plant cells, insect cells, and mammalian cells. Such expression can be carried out, for example, according to procedures known in the art. Exemplary eukaryotic cells that can be used to express the polypeptide include, but are not limited to, COS cells, including COS7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S, DG44, Lec13 CHO cells, and FUT8 CHO cells; PER.C6™ cells (Crucell); and NSO cells. In some embodiments, CLEC12a-binding polypeptides can be expressed in yeast. See, e.g., U.S. Patent Application Publication No. 2006 / 0270045. In some embodiments, a particular eukaryotic host cell is selected based on its ability to make desired post-translational modifications to the polypeptide. For example, in some embodiments, CHO cells produce polypeptides with higher levels of sialylation than the same polypeptides produced in 293 cells.

[0119] Introduction of one or more nucleic acids (e.g., vectors) into a desired host cell can be achieved by any method, including, but not limited to, calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid mediated transfection, electroporation, transduction, infection, etc. Non-limiting exemplary methods are described, for example, in Sambrook et al., Molecular Cloning, A Laboratory Manual, 3 rd ed. Cold Spring Harbor Laboratory Press (2001). Nucleic acids can be prepared by any suitable method. The vector may be transiently or stably transfected into the desired host cells.

[0120] Host cells containing any of the nucleic acids or vectors described herein are also provided. In some embodiments, a host cell expressing a CLEC12a-binding polypeptide described herein is provided. The CLEC12a-binding polypeptide expressed in the host cell can be purified by any suitable method, including, but not limited to, affinity matrix or hydrophobic interaction chromatography. Suitable affinity ligands include agents that bind to the ROR1 ECD and Fc region. For example, Protein A, Protein G, Protein A / G, or antibody affinity columns can be used to purify CLEC12a-binding polypeptides containing an Fc region by binding to the Fc region. Hydrophobic interaction chromatography, such as a butyl column or a phenyl column, can also be suitable for purifying some polypeptides, such as antibodies. Ion exchange chromatography (e.g., anion exchange chromatography and / or cation exchange chromatography) can also be suitable for purifying some polypeptides, such as antibodies. Mixed-mode chromatography (e.g., reversed-phase / anion exchange, reversed-phase / cation exchange, hydrophilic interaction / anion exchange, hydrophilic interaction / cation exchange, etc.) can also be suitable for purifying some polypeptides, such as antibodies. Many methods for purifying polypeptides are known in the art.

[0121] In some embodiments, the CLEC12a-binding polypeptide is produced in a cell-free system. Non-limiting exemplary cell-free systems are described, for example, in Sitaraman et al., Methods Mol. Biol. 498: 229-44 (2009), Spirin, Trends Biotechnol. 22: 538-45 (2004), Endo et al., Biotechnol. Adv. 21: 695-713 (2003).

[0122] In some embodiments, a CLEC12a-binding polypeptide produced by the above method is provided. In some embodiments, the CLEC12a-binding polypeptide is produced in a host cell. In some embodiments, the CLEC12a-binding polypeptide is produced in a cell-free system. In some embodiments, the CLEC12a-binding polypeptide is purified. In some embodiments, a cell culture medium comprising the CLEC12a-binding polypeptide is provided.

[0123] In some embodiments, a composition is provided comprising an antibody produced by the above method. In some embodiments, the composition comprises a CLEC12a-binding polypeptide produced in a host cell. In some embodiments, the composition comprises a CLEC12a-binding polypeptide produced in a cell-free system. In some embodiments, the composition comprises a purified CLEC12a-binding polypeptide.

[0124] Exemplary Methods of Treating Disease Using CLEC12a-Binding Polypeptides In some embodiments, methods are provided for treating a disease in an individual, comprising administering a CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide. In some embodiments, methods are provided for treating cancer in an individual. In some embodiments, methods are provided for treating a CLEC12a-expressing or CLEC12a-positive cancer in an individual. The methods comprise administering to the individual an effective amount of a CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide provided herein. In some embodiments, the CLEC12a-binding polypeptide is used to introduce a cytotoxic agent into cells expressing CLEC12a. In some such embodiments, the CLEC12a-binding polypeptide comprises a binding domain that binds to cytotoxic T cells or NK cells. In some such embodiments, the binding domain binds to CD3, T cell receptor (TCR) alpha, TCR beta, CD28, CD16, CD32A, CD64, CD89, NKp46, or NKG2D. In some embodiments, the binding domain may be a VHH domain, or an antibody binding domain comprising a heavy chain variable region and a light chain variable region, such as a VH / VL, scFv, or Fab fragment.

[0125] In some embodiments, the CLEC12a-binding polypeptide is linked to a cytotoxic agent to form an immunoconjugate. A variety of cytotoxic agents for use in immunoconjugates are known in the art and include, but are not limited to, calicheamicins, auristatins, dolastatins, tublysins, maytansinoids, cryptophycins, duocarmycins, esperamicins, pyrrolobenzodiazepines, and enediyne antibiotics.

[0126] In some embodiments, the CLEC12a-binding polypeptide is a chimeric antigen receptor expressed on a cytotoxic cell, such as a chimeric antigen receptor expressed on a T cell (CAR-T) or a chimeric antigen receptor expressed on a NK cell (CAR-NK). Such therapeutic methods can be in humans or animals. In some embodiments, methods of treating humans are provided.

[0127] Non-limiting exemplary cancers that may be treated with the CLEC12a-binding polypeptides or cells expressing a CLEC12a-binding polypeptide provided herein include, but are not limited to, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-dividing cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma, Waldenstrom's macroglobulinemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia. In some embodiments, the cancer is a CLEC12a-expressing (ie, CLEC12a-positive) cancer.

[0128] The CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide may be administered to a subject as needed. The frequency of administration can be determined by a skilled artisan, such as the attending physician, based on considerations such as the condition being treated, the age of the subject being treated, the severity of the condition being treated, and the general health of the subject being treated. In some embodiments, an effective dose of the CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide is administered to a subject one or more times. In some embodiments, an effective dose of the CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide is administered to a subject daily, twice a week, weekly, every two weeks, monthly, etc. An effective dose of the CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide is administered to a subject at least once. In some embodiments, an effective dose of a CLEC12a-binding polypeptide or cells expressing a CLEC12a-binding polypeptide may be administered multiple times, including multiple times over at least one month, at least six months, or at least one year.

[0129] In some embodiments, the pharmaceutical composition is administered in an amount effective to treat (including prevent) cancer. A therapeutically effective amount typically depends on the weight of the subject being treated, the subject's physical condition or health, the extent of the condition being treated, or the age of the subject being treated. Generally, the antibody may be administered in an amount ranging from about 0.05 mg / kg to about 100 mg / kg of body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 10 μg / kg to about 100 mg / kg of body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 50 μg / kg to about 5 mg / kg of body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 100 μg / kg to about 10 mg / kg of body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 100 μg / kg to about 20 mg / kg of body weight per dose. In some embodiments, the antibody is administered at a dose In some embodiments, the antibody may be administered in an amount ranging from about 0.5 mg / kg body weight to about 20 mg / kg body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 0.5 mg / kg body weight to about 10 mg / kg body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 0.05 mg / kg body weight to about 20 mg / kg body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 0.05 mg / kg body weight to about 10 mg / kg body weight per dose. In some embodiments, the antibody may be administered in an amount ranging from about 5 mg / kg body weight or less, e.g., less than 4 mg / kg, less than 3 mg / kg, less than 2 mg / kg, or less than 1 mg / kg of antibody.

[0130] In some embodiments, CLEC12a-binding polypeptides or cells expressing CLEC12a-binding polypeptides may be administered in vivo by a variety of routes, including, but not limited to, intravenous, intraarterial, parenteral, intraperitoneal, or subcutaneous administration. Appropriate formulations and administration routes may be selected depending on the intended use.

[0131] In some embodiments, therapeutic treatment using a CLEC12a-binding polypeptide is achieved by targeting a cytotoxic agent to cells that express CLEC12a, such as cancer cells that express CLEC12a. In some such embodiments, the CLEC12a-binding polypeptide is a chimeric antigen receptor expressed on cytotoxic cells, such as T cells or NK cells.

[0132] Pharmaceutical Composition In some embodiments, compositions comprising CLEC12a-binding polypeptides are provided in formulations comprising a wide variety of pharmaceutically acceptable carriers (see, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th ed. (2003), Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7 th ed., Lippencott Williams and Wilkins (2004), Kibbe et al., Handbook of Pharmaceutical Excipients, 3 rd ed., Pharmaceutical Press (2000). A variety of pharmaceutically acceptable carriers, including agents, adjuvants, and diluents, can be used. Additionally, a variety of pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents, etc., can also be used. Non-limiting exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.

[0133] In some embodiments, the pharmaceutical composition comprises a CLEC12a binding polypeptide at a concentration of at least 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, 125 mg / mL, 150 mg / mL, 175 mg / mL, 200 mg / mL, 225 mg / mL, or 250 mg / mL.

[0134] Combination therapy The CLEC12a-binding polypeptides or engineered cells of the present disclosure can be administered alone or in combination with other therapeutic modalities, such as other anti-cancer agents. The CLEC12a-binding polypeptides or engineered cells can be provided before, substantially simultaneously with, or after (i.e., simultaneously or sequentially with) other therapeutic modalities. In some embodiments, the therapeutic methods described herein can further include administering radiation therapy, chemotherapy, vaccination, targeted tumor therapy, CAR-T therapy, oncolytic virus therapy, cancer immunotherapy, cytokine therapy, surgical resection, chromatin modification, ablation, cryotherapy, an antisense agent directed against a tumor target, an siRNA agent directed against a tumor target, a microRNA agent directed against a tumor target, or an anti-cancer / anti-tumor agent, or a biologic such as an antibody, cytokine, or receptor extracellular domain-Fc fusion.

[0135] In some embodiments, the CLEC12a-binding polypeptides provided herein are given concomitantly with one or more chemotherapeutic agents, CAR-T (chimeric antigen receptor T-cell) therapies, oncolytic virus therapies, cytokine therapies, and / or agents targeting other checkpoint molecules such as VISTA, gpNMB, B7H4, HHLA2, CD73, CTLA4, TIGIT, etc.

[0136] In some embodiments, the CLEC12a-binding polypeptides or engineered cells of the disclosure are administered in combination with other anti-tumor agents, such as anti-HER-2 antibodies, anti-CD20 antibodies, epidermal growth factor receptor (EGFR) antagonists (e.g., tyrosine kinase inhibitors), HER1 / EGFR inhibitors (e.g., erlotinib (TARCEVA™)), platelet-derived growth factor inhibitors (e.g., GLEEVEC™ (imatinib mesylate)), COX-2 inhibitors (e.g., celecoxib), interferons, CTLA4 inhibitors (e.g., anti-CTLA antibody ipilimumab (YERVOY™)), PD-1 inhibitors (e.g., anti-PD1 antibodies, BMS-936558), PDL1 inhibitors (e.g., anti-PDL1 antibodies, MPDL3280A), PDL2 inhibitors (e.g., anti-PDL2 antibodies), cytokines, antagonists (e.g., neutralizing antibodies) that bind to one or more of the following targets: ErbB2 receptor, ErbB3 receptor, ErbB4 receptor, PDGFRβ receptor, BlyS receptor, APRIL receptor, BCMA receptor, PD-1 receptor, PDL1 receptor, PDL2 receptor, CTLA4 receptor, or VEGF receptor, TRAIL / Apo2, and other bioactive agents and organic chemical agents.

[0137] In some embodiments, the CLEC12a-binding polypeptides or engineered cells provided herein are given simultaneously with a PD-1 / PD-L1 therapeutic agent. Examples of PD-1 / PD-L1 therapeutic agents include nivolumab (BMS), pidilizumab (CureTech, CT-01 1), pembrolizumab (Merck), durvalumab (Medimmune / AstraZeneca), atezolizumab (Genentech / Roche), avelumab (Pfizer), AMP-224 (Amplimmune) , BMS-936559, AMP-514 (Amplimmune), MDX-1105 (Merck) , TSR-042 (Tesaro / AnaptysBio, ANB-011), STI-A1010 (Sorrento Therapeutics), STI-A1110 (Sorrento Therapeutics), and programs Other agents directed against death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are included.

[0138] In some embodiments, the CLEC12a-binding polypeptides or engineered cells of the present disclosure may be used in combination with chemotherapeutic agents, including, but not limited to, alkylating agents such as thiotepa and CYTOXAN™ cyclophosphamide; alkylsulfonates such as busulfan, improsulfan, and piposulfan; benzodopa, carboquone, and meturedopa. aziridines such as uredopa; altretamine, triethylenemelamine ethylenimines and methylamelamines, including triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; acetogenins (especially bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; kallistatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin); cryptophycins (especially cryptophycin 1) and cryptophycin 8); dolastatins; duocarmycins (including synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, fenesterine, prednimustine, trofos Nitrogen mustards such as famid and uracil mustard; nitrosourea such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; A. Enediyne antibiotics (e.g., calicheamicin, particularly calicheamicin γ1I and calicheamicin ω1I (e.g., Agnew, Chem Intl. Ed. Engl., 33: 183-186 (1994)) dynemicins, including dynemicin A; bisphosphonates such as clodronate; esperamicin; and neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, anthramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detol Bicine, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN™ doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, porfiromycin, Antibiotics such as puromycin, quelamycin, rhodrubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, and trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; and Pyrimidine analogues such as citabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calsterone, drostanolone propionate, epithiostanol, mepitiostane, and testolactone; anti-adrenals such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as furoic acid; aceglatone; aldophosph Amidoglycosides; Aminolevulinic acid; Eniluracil; Amsacrine; Bestravcil; Bisantrene; Edatrexate; Defofamine; Demecolcine; Diaziquone; Eflornithine; Elliptinium acetate; Epothilone etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK™ polysaccharide complex (JHS Natural Products, Eugene, Oregon; razoxane; rhizoxin; schizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, such as TAXOL™ paclitaxel (Bristol-Myers Squibb Oncology, Princeton, New Jersey), ABRAXANE (trademark a Cremophor-free albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumburg, IL), and TAXOTERE™ doxetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine in GEMZAR®; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine in NAVELBINE®; novantrone; teniposide; edatrexate; daunomycin; aminopterin; Xeloda; ibandronate; irinotecan (Camptosar, CPT-11) (including treatment regimens of irinotecan with 5-FU and leucovorin); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin, including the oxaliplatin treatment regimen (FOLFOX); PKCα, Raf, and H-Ras, which reduce cell proliferation , inhibitors of EGFR (e.g., erlotinib (TARCEVA™)) and VEGF-A, as well as pharmaceutically acceptable salts, acids, or derivatives of any of the above.

[0139] Further non-limiting exemplary chemotherapeutic agents include antihormonal agents that act to regulate or inhibit hormone action on cancer, such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including the tamoxifen in NOLVADEX™), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, ketoxifene, LY117018, onapristone, and toremifene in FARESTON™; aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazole, aminoglutethimide, megestrol acetate in MEGASE™, exemestane, formestane, fadrozole, vorozole in RIVISOR™, letrozole in FEMARA™, and anastrozole in ARIMIDEX™; and flutamivir. antiandrogens such as benzodiazepine, nilutamide, bicalutamide, leuprolide, and goserelin; and troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); antisense oligonucleotides, particularly those that inhibit the expression of genes in signaling pathways involved in abnormal cell proliferation, such as PKCα, Ralf, and H-Ras; ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME™ ribozyme) and HER2 expression inhibitors; gene therapy vaccines, such as ALLOVECTIN™ vaccine, LEUVECTIN™ vaccine, and VAXID™ vaccine; rIL-2 in PROLEUKIN™ (aldesleukin); topoisomerase 1 inhibitors in LURTOTECAN™; GnRH agonists in ABARELIX™; and pharmaceutically acceptable salts, acids, or derivatives of any of the above.

[0140] In some embodiments, the CLEC12a-binding polypeptide and the additional agent are formulated into a single therapeutic composition, and the CLEC12a-binding polypeptide and the additional agent are administered simultaneously. Alternatively, the CLEC12a-binding polypeptide or engineered cells and the additional agent are separate from one another, e.g., formulated into separate therapeutic compositions, and the CLEC12a-binding polypeptide or engineered cells and the additional agent are administered simultaneously, or the CLEC12a-binding polypeptide or engineered cells and the additional agent are administered at different times during the treatment regimen. For example, the CLEC12a-binding polypeptide or engineered cells are administered before the administration of the additional agent, the CLEC12a-binding polypeptide or engineered cells are administered after the administration of the additional agent, or the CLEC12a-binding polypeptide or engineered cells and the additional agent are administered alternately. The CLEC12a-binding polypeptide and the additional agent may be administered in a single dose or multiple doses.

[0141] In some embodiments, the CLEC12a-binding polypeptide or engineered cells and the additional agent(s) are administered simultaneously. For example, the CLEC12a-binding polypeptide and the additional agent(s) may be formulated in a single composition or may be administered as two or more separate compositions. In some embodiments, the CLEC12a-binding polypeptide or engineered cells and the additional agent(s) are administered sequentially, or the CLEC12a-binding polypeptide or engineered cells and the additional agent(s) are administered at different times during a treatment regimen.

[0142] Non-Limiting Exemplary Methods of Diagnosis and Treatment In some embodiments, the methods described herein are useful for evaluating a subject and / or a sample from a subject (e.g., a cancer patient). In some embodiments, the evaluation is one or more of diagnosis, prognosis, and / or response to treatment.

[0143] In some embodiments, the methods described herein include assessing the presence, absence, or level of a protein. In some embodiments, the methods described herein include assessing the presence, absence, or level of expression of a nucleic acid. The compositions described herein can be used for these measurements. For example, in some embodiments, the methods described herein include contacting a tumor specimen or cells cultured from the tumor with a therapeutic agent described herein.

[0144] In some embodiments, the evaluation may prescribe treatment (including treatment with an antibody described herein). In some embodiments, the evaluation may prescribe the use or withholding of adjuvant therapy after resection. Adjuvant therapy, also called adjuvant therapy, is treatment given in addition to primary, definitive, or initial treatment. As a non-limiting example, adjuvant therapy may be additional treatment, usually given after surgery, when all detectable disease has been removed but there remains a statistical risk of relapse due to latent disease. In some embodiments, the polypeptide is used as an adjuvant therapy in the treatment of cancer. In some embodiments, the polypeptide is used as the sole adjuvant therapy in the treatment of cancer. In some embodiments, the polypeptides described herein are withheld as adjuvant therapy in the treatment of cancer. For example, if a patient is unlikely to respond or has only a minimal response to an antibody described herein, treatment may be withheld for quality of life and to avoid unnecessary toxicity from ineffective chemotherapy. In such cases, palliative care may be used.

[0145] In some embodiments, the polypeptide is administered as a neoadjuvant therapy before resection. In some embodiments, neoadjuvant therapy refers to a therapy that shrinks and / or downgrades a tumor before any surgery. In some embodiments, neoadjuvant therapy refers to a chemotherapy drug administered to a cancer patient before surgery. In some embodiments, neoadjuvant therapy refers to an antibody administered to a cancer patient before surgery. Cancer types for which neoadjuvant chemotherapy is typically considered include, for example, breast cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, and lung cancer. In some embodiments, the polypeptide is used as a neoadjuvant therapy in the treatment of cancer. In some embodiments, the use is before resection.

[0146] In some embodiments, the tumor microenvironment contemplated by the methods described herein is one or more of tumor vasculature, tumor-infiltrating lymphocytes, fibroblastic reticular cells, endothelial progenitor cells (EPCs), cancer-associated fibroblasts, pericytes, other stromal cells, components of the extracellular matrix (ECM), dendritic cells, antigen-presenting cells, T cells, regulatory T cells, macrophages, other lymphoid cells, neutrophils, and other immune cells located in proximity to the tumor.

[0147] kit Also provided are articles of manufacture and kits comprising any of the CLEC12a-binding polypeptides described herein and suitable packaging. In some embodiments, the invention includes a kit comprising (i) a CLEC12a-binding polypeptide and (ii) instructions for using the kit to administer the CLEC12a-binding polypeptide to an individual.

[0148] Suitable packaging for the compositions described herein is known in the art and includes, for example, vials (e.g., sealed vials), containers, ampoules, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. These articles of manufacture may be further sterilized and / or sealed. Unit dosage forms comprising the compositions described herein are also provided. These unit dosage forms may be stored in suitable packaging in single or multi-unit dosage form, which may also be sterilized and sealed. Instructions for use provided in the kits of the present invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but may also be machine-readable. Readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable. Instructions for use of the antibody will generally include information regarding dosage, administration schedule, and route of administration for the intended therapeutic or industrial use. The kit may further include instructions for selecting an appropriate individual treatment.

[0149] The containers may be unit doses, bulk packages (e.g., multi-dose packages), or sub-unit doses. Kits may also be provided that contain a sufficient dose of a molecule disclosed herein to provide effective treatment to an individual over an extended period of time, such as, for example, any approximate period of 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the molecule and instructions for use, and may be packaged in an amount sufficient for storage and use in pharmacies, e.g., hospital pharmacies and compounding pharmacies. In some embodiments, the kits include a dried (e.g., lyophilized) composition that can be reconstituted, resuspended, or rehydrated to form a generally stable aqueous suspension of the antibody. [Example]

[0150] The examples discussed below are intended to be purely illustrative of the present invention and should not be construed as limiting the present invention in any way. These examples are not intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure.

[0151] Example 1: CLEC12a single domain antibody Single-domain antibodies targeting human CLEC12a were generated through immunization of llamas and alpacas with a recombinant form of the human CLEC12a extracellular domain.

[0152] After specific anti-CLEC12a antibody titers were generated, llama / alpaca peripheral blood mononuclear cells (PBMCs) were isolated from 500 mL of blood from the immunized animals. Total mRNA was isolated using the Qiagen RNeasy Maxi kit and subsequently converted to first-strand cDNA using Thermo Superscript IV reverse transcriptase and oligo-dT priming. This cDNA was used as a template to specifically amplify VHH sequences via PCR and cloned into a yeast surface display vector as VHH-Fc-AGA2 fusion proteins.

[0153] Using recombinant CLEC12a ECD, we enriched a yeast library displaying VHH-Fc-AGA2 fusion proteins via magnetic bead separation followed by fluorescence-activated cell sorting (FACS). Selected yeast were plated out, and isolated colonies were picked and placed in 96-well blocks and grown in a medium that switches expression from surface-displayed VHH-Fc to secretion into the culture medium. Supernatants from 96-well yeast secretion cultures were applied to 293F cells transiently transfected with CLEC12a (CLEC12a-positive) or untransfected 293F cells (CLEC12a-negative), washed, treated with a fluorophore-labeled anti-human IgG1 Fc secondary antibody, and analyzed by 96-well flow cytometry.

[0154] Nucleic acid sequences encoding VHHs that bind to CLEC12a-positive cells but not to CLEC12a-negative cells were cloned in frame with the human Fc-coding region into mammalian expression vectors and expressed by transient transfection using polyethyleneimine in HEK293 Freestyle cells (293F cells) or CHO cells. After 3 to 7 days, supernatants were collected, and secreted recombinant proteins were analyzed by Protein A chromosome analysis. The concentration was calculated from the absorbance at 280 nm and the extinction coefficient.

[0155] The epitopes of single domain antibodies (sdAbs) containing VHH domains that bind to CLEC12a were compared using biolayer interferometry. 7 μg / mL of mFc-CLEC12a-ECD (SEQ ID NO: 87) was immobilized on a capture sensor coated with anti-mFc. 100 nM of one sdAb was then loaded onto the CLEC12a antigen and allowed to equilibrate. The sensor was then transferred to 100 nM of a second sdAb. An increase in assay signal indicates binding, indicating that the second sdAb targets an epitope different from that of the first sdAb.

[0156] Camelid-derived CLEC12a using human VH3-23 germline as a scaffold The VHHs were humanized. The remainder of the Camelidae family, which contributes to solubility, specificity, stability, and / or affinity, was left unmodified. Furthermore, where possible and necessary, amino acid sequences that could potentially be detrimental to developability were modified to mitigate this risk. Furthermore, all humanized variants contained the Leu11Glu (L11E) modification described in U.S. Patent Application Publication No. 2016 / 0207981.

[0157] These results indicate that three distinct epitopes were found among the humanized versions of the MB11, ME06, MC02, MH07, MC06, and ME02 sdAbs. As shown in Figure 1A, the hzME02v4 and hzME06v16 sdAbs share different epitopes than the hzMB11v13, hzMC02v6, hzMH07v3, and hzMC06v2 sdAbs. As shown in Figure 1B, none of the hzME06v16, hzME02v4, and hzMB11v13 sdAbs share a common epitope. A summary of the results is shown in Table 3 below.

[0158] [Table 3]

[0159] Example 2: Binding of polypeptides to CLEC12a Binding of sdAbs to human CLEC12a was assessed by flow cytometry. Each sdAb contained the VHH domain shown in Table 4 below and the Fc region of human IgG1 xELL, in which amino acids Glu233, Leu234, and Leu235 (EU numbering) were deleted (SEQ ID NO: 51). HEK293 cells were transiently transfected with a plasmid encoding CLEC12a (UniProt accession number Q5QGZ9.3; SEQ ID NO: 1) and used as a positive cell line, while untransfected HEK293 cells were used as CLEC12a-negative cells. Each cell type was seeded at 30,000 cells / well in FACS buffer (PBS 1% BSA, 0.1% NaN3 pH 7.4) in 96-well round-bottom plates. sdAbs were diluted in 11-point 3-fold serial dilutions in FACS buffer. The sdAb dilutions were applied to the seeded cells. The antibody was added and the assay plate was incubated for 30 minutes at 4° C. After washing twice in 150 μL of FACS buffer, the cells in each well were resuspended in 100 μL of a 1:2000 dilution of Alexa Fluor 647-conjugated secondary anti-human IgG in FACS buffer and incubated for 30 minutes at 4° C. After washing the cells two more times, bound antibody was detected by flow cytometry.

[0160] Flow cytometry analysis was performed on Intellicyte's iQue Plus, and fluorescence was analyzed. The apparent affinity (K d , nM) was determined using one-site binding nonlinear regression in PRISM graphing software.

[0161] As shown in Figures 2A-2L, the sdAbs tested exhibited CLEC12a binding and no or minimal binding to untransfected HEK293 cells that do not express CLEC12a. The apparent binding affinities are shown in Table 4 below.

[0162] [Table 4]

[0163] The present disclosure may be embodied in other specific forms without departing from the spirit or essential characteristics of the present disclosure. Accordingly, the above-described embodiments are to be considered in all respects as illustrative and not limiting of the present disclosure. The scope of the present disclosure is therefore indicated by the appended claims, rather than the above detailed description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

[0164] [Table 5] TIFF0007824999000006.tif243170TIFF0007824999000007.tif244170TIFF0007824999000008.tif242170 TIFF0007824999000009.tif251170TIFF0007824999000010.tif246170TIFF0007824999000011.tif171170

Claims

1. A polypeptide comprising at least one VHH domain that binds to CLEC12a, A polypeptide, wherein at least one VHH domain comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NO:47, SEQ ID NO:48, and SEQ ID NO:49, respectively.

2. The polypeptide of claim 1, wherein at least one VHH domain is humanized.

3. 3. The polypeptide of claim 1 or 2, wherein at least one VHH domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 31 or SEQ ID NO:

99.

4. The polypeptide according to any one of claims 1 to 3, wherein at least one VHH domain comprises the amino acid sequence of SEQ ID NO: 31 or SEQ ID NO:

99.

5. A polypeptide according to any one of claims 1 to 4, comprising two VHH domains.

6. A polypeptide according to any one of claims 1 to 4, comprising three VHH domains.

7. The polypeptide of any one of claims 1 to 6, wherein the polypeptide comprises at least one binding domain that binds to an antigen other than CLEC12a.

8. 8. The polypeptide of claim 7, wherein the polypeptide comprises at least one binding domain that binds to CD3, T cell receptor (TCR) alpha, TCR beta, CD28, CD16, CD32A, CD64, CD89, NKp46, or NKG2D.

9. A polypeptide according to claim 5 or 6, wherein each VHH domain binds to CLEC12a.

10. The polypeptide of claim 9 , wherein each VHH domain comprises the same CDR1, CDR2, and CDR3 amino acid sequences.

11. The polypeptide of claim 9 , wherein each VHH domain comprises the same VHH sequence.

12. A polypeptide according to any one of claims 1 to 4, comprising one VHH domain.

13. The polypeptide of any one of claims 1 to 12, wherein the polypeptide comprises an Fc region.

14. The polypeptide of claim 13, wherein the Fc region comprises an amino acid sequence selected from SEQ ID NO: 50 to SEQ ID NO:

85.

15. 15. The polypeptide of claim 13 or 14, which forms a dimer under physiological conditions.

16. The polypeptide according to any one of claims 1 to 15, wherein the CLEC12a is human CLEC12a.

17. The polypeptide of claim 16, wherein the human CLEC12a comprises the sequence of SEQ ID NO:

1.

18. An immunoconjugate comprising a polypeptide according to any one of claims 1 to 17 and a cytotoxic agent.

19. 19. The immunoconjugate of claim 18, wherein the cytotoxic agent is selected from a calicheamicin, an auristatin, a dolastatin, a tublysin, a maytansinoid, a cryptophycin, a duocarmycin, an esperamicin, a pyrrolobenzodiazepine, and an enediyne antibiotic.

20. A pharmaceutical composition comprising the polypeptide of any one of claims 1 to 17 or the immunoconjugate of claim 18 or 19, and a pharmaceutically acceptable carrier.

21. An isolated nucleic acid encoding a polypeptide according to any one of claims 1 to 17.

22. A vector comprising the nucleic acid of claim 21.

23. 23. A host cell comprising the nucleic acid of claim 21 or the vector of claim 22.

24. A host cell expressing a polypeptide according to any one of claims 1 to 17.

25. 28. A method for producing a polypeptide according to any one of claims 1 to 17, comprising incubating a host cell according to claim 23 or 24 under conditions suitable for expression of said polypeptide.

26. 26. The method of claim 25, further comprising isolating the polypeptide.

27. A pharmaceutical composition for treating cancer, comprising a polypeptide according to any one of claims 1 to 17, an immunoconjugate according to claim 18 or 19, or a pharmaceutical composition according to claim 20.

28. 28. The pharmaceutical composition of claim 27, wherein the cancer is selected from lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-dividing cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), hairy cell leukemia, and chronic myeloblastic leukemia.

29. 29. The pharmaceutical composition of claim 27 or 28, wherein the cancer is acute myeloid leukemia (AML).

30. A pharmaceutical composition according to any one of claims 27 to 29 for use in combination with an additional therapeutic agent.

31. 31. The pharmaceutical composition of claim 30, wherein the additional therapeutic agent is an anti-cancer agent.

32. 32. The pharmaceutical composition of claim 31, wherein the anti-cancer agent is selected from a chemotherapeutic agent, an anti-cancer biologic, radiation therapy, a CAR-T therapeutic agent, and an oncolytic virus.

33. The pharmaceutical composition according to any one of claims 27 to 32, wherein the cancer is a cancer that expresses CLEC12a.

Images